Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis

Journal of Neuroinflammation

Murali Ramanathan³  Niels Bergsland¹  Jacqueline Durfee¹  Marc Weiskopf²  Bijal Mehta²  Sara Hussein¹  Barbara Teter²  Jaclyn Schneider²  Allison Drake²  Ellen Carl¹  Naeem Mahfooz²  Robert Zivadinov¹  Bianca Weinstock-Guttman² 

[1] Bufalo Neuroimaging Analysis Center, Department of Neurology, State University of New York, Buffalo, NY, USA;Department of Neurology, State University of New York, Buffalo, NY, USA;Department of Pharmaceutical Sciences, State University of New York, Buffalo, NY, USA

关键词: brain atrophy;    lesion volume;    gene-environment interactions;    environmental factors;    MRI;    lipid profile;    diet;    Multiple sclerosis;   

Others  :  1213097
DOI  :  10.1186/1742-2094-8-127

 received in 2011-04-24, accepted in 2011-10-04,  发布年份 2011

【 摘 要 】

Background

The breakdown of the blood-brain-barrier vascular endothelium is critical for entry of immune cells into the MS brain. Vascular co-morbidities are associated with increased risk of progression. Dyslipidemia, elevated LDL and reduced HDL may increase progression by activating inflammatory processes at the vascular endothelium.

Objective

To assess the associations of serum lipid profile variables (triglycerides, high and low density lipoproteins (HDL, LDL) and total cholesterol) with disability and MRI measures in multiple sclerosis (MS).

Methods

This study included 492 MS patients (age: 47.1 ± 10.8 years; disease duration: 12.8 ± 10.1 years) with baseline and follow-up Expanded Disability Status Score (EDSS) assessments after a mean period of 2.2 ± 1.0 years. The associations of baseline lipid profile variables with disability changes were assessed. Quantitative MRI findings at baseline were available for 210 patients.

Results

EDSS worsening was associated with higher baseline LDL (p = 0.006) and total cholesterol (p = 0.001, 0.008) levels, with trends for higher triglyceride (p = 0.025); HDL was not associated. A similar pattern was found for MSSS worsening. Higher HDL levels (p < 0.001) were associated with lower contrast-enhancing lesion volume. Higher total cholesterol was associated with a trend for lower brain parenchymal fraction (p = 0.033).

Conclusions

Serum lipid profile has modest effects on disease progression in MS. Worsening disability is associated with higher levels of LDL, total cholesterol and triglycerides. Higher HDL is associated with lower levels of acute inflammatory activity.

【 授权许可】

   
2011 Weinstock-Guttman et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Frohman EM, Racke MK, Raine CS: Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med 2006, 354:942-955.
• [2]Lucchinetti CF, Bruck W, Lassmann H: Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol 2004, 56:308.
• [3]Gotthardt M, Trommsdorff M, Nevitt MF, Shelton J, Richardson JA, Stockinger W, Nimpf J, Herz J: Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular communication and signal transduction. J Biol Chem 2000, 275:25616-25624.
• [4]Stockinger W, Brandes C, Fasching D, Hermann M, Gotthardt M, Herz J, Schneider WJ, Nimpf J: The reelin receptor ApoER2 recruits JNK-interacting proteins-1 and -2. J Biol Chem 2000, 275:25625-25632.
• [5]Roheim PS, Carey M, Forte T, Vega GL: Apolipoproteins in human cerebrospinal fluid. Proc Natl Acad Sci USA 1979, 76:4646-4649.
• [6]Borghini I, Barja F, Pometta D, James RW: Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochim Biophys Acta 1995, 1255:192-200.
• [7]Mockel B, Zinke H, Flach R, Weiss B, Weiler-Guttler H, Gassen HG: Expression of apolipoprotein A-I in porcine brain endothelium in vitro. J Neurochem 1994, 62:788-798.
• [8]Assmann G, Gotto AM Jr: HDL cholesterol and protective factors in atherosclerosis. Circulation 2004, 109:III8-14.
• [9]Burger D, Dayer JM: High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation? Autoimmun Rev 2002, 1:111-117.
• [10]Scanu A, Molnarfi N, Brandt KJ, Gruaz L, Dayer JM, Burger D: Stimulated T cells generate microparticles, which mimic cellular contact activation of human monocytes: differential regulation of pro- and anti-inflammatory cytokine production by high-density lipoproteins. J Leukoc Biol 2008, 83:921-927.
• [11]Ferretti G, Bacchetti T, Principi F, Di Ludovico F, Viti B, Angeleri VA, Danni M, Provinciali L: Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity. Mult Scler 2005, 11:677-682.
• [12]Jamroz-Wisniewska A, Beltowski J, Stelmasiak Z, Bartosik-Psujek H: Paraoxonase 1 activity in different types of multiple sclerosis. Mult Scler 2009, 15:399-402.
• [13]Cybulsky MI, Gimbrone MA Jr: Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991, 251:788-791.
• [14]Sitia S, Tomasoni L, Atzeni F, Ambrosio G, Cordiano C, Catapano A, Tramontana S, Perticone F, Naccarato P, Camici P, et al.: From endothelial dysfunction to atherosclerosis. Autoimmun Rev 2010, 9:830-834.
• [15]Stokes KY, Calahan L, Hamric CM, Russell JM, Granger DN: CD40/CD40L contributes to hypercholesterolemia-induced microvascular inflammation. Am J Physiol Heart Circ Physiol 2009, 296:H689-697.
• [16]Esteve E, Ricart W, Fernandez-Real JM: Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr 2005, 24:16-31.
• [17]Torres A, Askari AD, Malemud CJ: Cardiovascular disease complications in systemic lupus erythematosus. Biomark Med 2009, 3:239-252.
• [18]Boyer JF, Gourraud PA, Cantagrel A, Davignon JL, Constantin A: Traditional cardiovascular risk factors in rheumatoid arthritis: A meta-analysis. Joint Bone Spine 2010.
• [19]von Eckardstein A, Sibler RA: Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Curr Opin Lipidol 2010.
• [20]Li Y, Wang H, Hu X, Peng F, Yang Y: Serum lipoprotein levels in patients with neuromyelitis optica elevated but had little correlation with clinical presentations. Clin Neurol Neurosurg 2010, 112:478-481.
• [21]Giubilei F, Antonini G, Di Legge S, Sormani MP, Pantano P, Antonini R, Sepe-Monti M, Caramia F, Pozzilli C: Blood cholesterol and MRI activity in first clinical episode suggestive of multiple sclerosis. Acta Neurol Scand 2002, 106:109-112.
• [22]Marrie RA, Rudick R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T: Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010, 74:1041-1047.
• [23]McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, et al.: Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50:121-127.
• [24]Zivadinov R, Reder AT, Filippi M, Minagar A, Stuve O, Lassmann H, Racke MK, Dwyer MG, Frohman EM, Khan O: Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008, 71:136-144.
• [25]Zivadinov R, Weinstock-Guttman B, Zorzon M, Uxa L, Serafin M, Bosco A, Bratina A, Maggiore C, Grop A, Tommasi MA, et al.: Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. J Neuroimmunol 2009, 209:123-130.
• [26]Zivadinov R, Weinstock-Guttman B, Hashmi K, Abdelrahman N, Stosic M, Dwyer M, Hussein S, Durfee J, Ramanathan M: Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology 2009, 73:504-510.
• [27]Jorgensen B, Tsao M: Dispersion models and longitudinal data analysis. Stat Med 1999, 18:2257-2270.
• [28]Alexander JS, Harris MK, Wells SR, Mills G, Chalamidas K, Ganta VC, McGee J, Jennings MH, Gonzalez-Toledo E, Minagar A: Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b. Mult Scler 2010, 16:801-809.
• [29]Minagar A, Jy W, Jimenez JJ, Alexander JS: Multiple sclerosis as a vascular disease. Neurol Res 2006, 28:230-235.
• [30]Inglese M, Park SJ, Johnson G, Babb JS, Miles L, Jaggi H, Herbert J, Grossman RI: Deep gray matter perfusion in multiple sclerosis: dynamic susceptibility contrast perfusion magnetic resonance imaging at 3 T. Arch Neurol 2007, 64:196-202.
• [31]De Keyser J, Steen C, Mostert JP, Koch MW: Hypoperfusion of the cerebral white matter in multiple sclerosis: possible mechanisms and pathophysiological significance. J Cereb Blood Flow Metab 2008, 28:1645-1651.
• [32]Swank RL, Dugan BB: Effect of low saturated fat diet in early and late cases of multiple sclerosis. Lancet 1990, 336:37-39.
• [33]Zhang SM, Willett WC, Hernan MA, Olek MJ, Ascherio A: Dietary fat in relation to risk of multiple sclerosis among two large cohorts of women. Am J Epidemiol 2000, 152:1056-1064.
• [34]Willey JZ, Elkind MS: 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol 2010, 67:1062-1067.
• [35]Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS: The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002, 420:78-84.
• [36]Maier O, De Jonge J, Nomden A, Hoekstra D, Baron W: Lovastatin induces the formation of abnormal myelin-like membrane sheets in primary oligodendrocytes. Glia 2009, 57:402-413.
• [37]Klopfleisch S, Merkler D, Schmitz M, Kloppner S, Schedensack M, Jeserich G, Althaus HH, Bruck W: Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo. J Neurosci 2008, 28:13609-13614.
• [38]Sellner J, Weber MS, Vollmar P, Mattle HP, Hemmer B, Stuve O: The Combination of Interferon-Beta and HMG-CoA Reductase Inhibition in Multiple Sclerosis: Enthusiasm Lost too Soon? CNS Neurosci Ther 2010.
• [39]Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M, Singh I: Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004, 363:1607-1608.
• [40]Rudick RA, Pace A, Rani MR, Hyde R, Panzara M, Appachi S, Shrock J, Maurer SL, Calabresi PA, Confavreux C, et al.: Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology 2009, 72:1989-1993.
• [41]Waubant E, Pelletier D, Mass M, Cohen J, Kita M, Cross A, Bar-Or A, Vollmer T, Racke MK, Stüve O, et al.: Atorvastatin therapy in patients with Clinically Isolated Syndrome (CIS): the STAyCIS study. 134th Annual Meeting, American Neurological Assocation; Baltimore, MD 2010.
• [42]Markovic-Plese S, Jewells V, Speer D: Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 2009, 72:1965-1966. 1965; author reply
• [43]Sorensen PS, Lycke J, Eralinna JP, Edland A, Wu X, Frederiksen JL, Oturai A, Malmestrom C, Stenager E, Sellebjerg F, Sondergaard HB: Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol 2011, 10:691-701.